Europe Branded Generics Market, Size, Segment and Growth by Forecast Period: 2023-2028
The branded generics market in Europe is expected to grow from US$ 45.81 billion in 2022 to US$ 81.30 billion by 2028; it is estimated to grow at a CAGR of 10.0% from 2022 to 2028.
Players in the pharmaceutical industry are adopting various
strategies, including product differentiation, to reduce development costs and
maximize profits. Product differentiation involves developing innovative
products based on an existing product by enhancing its features, performance,
and efficacy. Product differentiation paves the way for strengthening product
pipeline and lifecycle management. As generic drugs contain the same active
pharmaceutical ingredients as the brand-name products, differentiation in
color, shape, taste, inactive ingredients, preservatives, and packaging result
in high demand for branded generics. Therefore, differentiation in the final
product is expected to offer lucrative growth opportunities for the competitive
players in the market in the coming years.
๐Download Full PDF Sample
Copy of Market Report @
https://wwcw.businessmarketinsights.com/sample/BMIRE00026048
Additionally, prominent players operating the market are
offering low-cost branded generics to remain competitive in the market. For
instance, in July 2020, Takeda Pharmaceutical Company announced a joint venture
with Teva Pharmaceuticals Industries Ltd. to commercialize complex generics
products, specialty assets, and other pipeline generic medicines. Further, key
players in the branded generics segment offer low-cost branded generics to
remain competitive in the Europe market. This can be achieved by strategically
sourcing raw materials from emerging economies and partnering with suppliers.
All these factors would provide lucrative opportunities for the overall branded
generics market growth during the forecast period.
By introducing new features and technologies, vendors in the
Europe branded generics market can attract new customers and expand their
footprints in emerging markets. This factor is likely to drive the market at a
good CAGR during the forecast period.
Europe Branded Generics Strategic Insights
Strategic insights for the Europe Branded Generics provides
data-driven analysis of the industry landscape, including current trends, key
players, and regional nuances. These insights offer actionable recommendations,
enabling readers to differentiate themselves from competitors by identifying
untapped segments or developing unique value propositions. Leveraging data
analytics, these insights help industry players anticipate the market shifts,
whether investors, manufacturers, or other stakeholders. A future-oriented
perspective is essential, helping stakeholders anticipate market shifts and
position themselves for long-term success in this dynamic region. Ultimately,
effective strategic insights empower readers to make informed decisions that
drive profitability and achieve their business objectives within the market.
key company profiles
Aspen Holdings
AstraZeneca
Bausch Health
(Valeant Pharmaceuticals)
Dr. Reddy's
Laboratories Inc.
GlaxoSmithKline plc
Hetero
Lupin
MYLAN N.V.
Par Pharmaceuticals
Sandoz
International Gmbh
Europe Branded Generics Regional Insights
The geographic scope of the Europe Branded Generics refers
to the specific areas in which a business operates and competes. Understanding
local distinctions, such as diverse consumer preferences (e.g., demand for
specific plug types or battery backup durations), varying economic conditions,
and regulatory environments, is crucial for tailoring strategies to specific
markets. Businesses can expand their reach by identifying underserved areas or
adapting their offerings to meet local demands. A clear market focus allows for
more effective resource allocation, targeted marketing campaigns, and better
positioning against local competitors, ultimately driving growth in those
targeted areas.
Europe Branded Generics Market Segmentation
Europe branded generics market is segmented into therapeutic
application, distribution channel, drug class, formulation type and country.
The therapeutic application segment of the Europe branded generics market is
segmented into oncology, cardiovascular diseases, diabetes, neurology,
gastrointestinal diseases, dermatology diseases, and analgesics and
anti-inflammatory. In 2022, the others segment held the largest share of the
market, by therapeutic application. The Europe branded generics market, by distribution
channel is hospital pharmacies, retail pharmacies, online pharmacies, and drug
stores. The retail pharmacies segment is likely to hold the largest share of
the market in 2022. The Europe branded generics market, by drug class is
segmented into alkylating agents, antimetabolites, hormones, anti-hypertensive,
lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptic, and
others. The others segment is likely to hold the largest share of the market in
2022. The Europe branded generics market, based on formulation type is
segmented into oral, parenteral, topical, and other. In 2022, the oral segment
held the largest share of the market, by formulation type. Based on country,
the Europe branded generics market is segmented into France, Germany, Italy,
UK, Spain, and the Rest of Europe. The Rest of Europe held the largest market
share in 2022.
About Us:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Dรฉfense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications
Author's Bio
Akshay
Senior Market Research Expert at Business Market Insights
Comments
Post a Comment